| HOME >> BIOLOGY >> TECHNOLOGY |
Myriad Genetics
deCODE Genetics
Risk of Developing Alzheimer's Disease
Athena Diagnostics
Innogenetics
Risk of Cardiovascular Diseases
deCODE Genetics
Other Emerging Molecular Tests for Predicting Risk of Disease
CombiMatrix
deCODE Genetics
3.5. Tables
Chapter 4
BUSINESS CONSIDERATIONS IN MOLECULAR DIAGNOSTICS
4.1. Molecular Diagnostics Market Overview
4.2. Major Trends in the Molecular Diagnostics Market
Automation, Ease of Use
Moving Selected Molecular Diagnostic Tests Nearer to the Patient
Growth in Number of New Biomarkers
Increasing Efforts on Clinical Validation of Tests
Increasing Number of Tests Commercially Available
Launching New Tests Through CLIA-Certified Laboratories
Impact of FDA Regulations
Growing Number of FDA-Cleared and Approved Tests
Consolidation (Acquisitions)
Competition
Increasing Role of Personalized Medicine
4.3. Personalized Medicine and Molecular Diagnostics
Treatment of Infectious Diseases
Companion Diagnostics and Targeted Therapies
Other Personalized Medicine Tests
4.4. Major Challenges Facing Molecular Diagnostic Companies
Challenges Associated with Personalized Medicine Market Segment
Regulatory Issues and Considerations
Regulatory Issues and Considerations for Molecular Diagnostics Clinical Laboratories
Regulatory Issues and Considerations for Molecular Diagnostic Companies
Regulatory Issues and Consideration for Pharmaceutical Companies Developing Pharmacogenomic Therapies
Reimbursement of Molecular Diagnostics
Patient and Physician Education
Identification of New Biomarkers; Validation
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |